Markers of B-cell activation in relation to risk of non-hodgkin lymphoma

Cancer Research

Volumn 72, Issue 18, 2012, Pages 4733-4743

  De Roos, Anneclaire J ^a,b   Mirick, Dana K ^a   Edlefsen, Kerstin L ^b   LaCroix, Andrea Z ^a,b   Kopecky, Kenneth J ^a   Madeleine, Margaret M ^a,b   Magpantay, Larry ^c   Martińez Maza, Otoniel ^c,d  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD23 ANTIGEN; CD27 ANTIGEN; CD30 ANTIGEN; CXCL13 CHEMOKINE; HERMES ANTIGEN;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; B LYMPHOCYTE ACTIVATION; BODY MASS; CANCER CLASSIFICATION; CANCER RISK; CARCINOGENESIS; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; EDUCATION; ETHNIC DIFFERENCE; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; NEGRO; NONHODGKIN LYMPHOMA; OBSERVATIONAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREND STUDY;

AGED; B-LYMPHOCYTES; CASE-CONTROL STUDIES; FEMALE; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84866421141     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-1639     Document Type: Article

References (33)

1. Schwartz RS. Immunodeficiency, immunosuppression, and susceptibility to neoplasms. J Natl Cancer Inst Monogr 2001;28:5-9.
2. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007;370:59-67.
3. Koshiol J, Lam TK, Gridley G, Check D, Brown LM, Landgren O. Racial differences in chronic immune stimulatory conditions and risk of non- Hodgkin's lymphoma in veterans from the United States. J Clin Oncol 2011;29:378-85.
4. Yawetz S, Cumberland WG, van der MM, Martinez-Maza O. Elevated serum levels of soluble CD23 (sCD23) precede the appearance of acquired immunodeficiency syndrome-associated non-Hodgkin's lymphoma. Blood 1995;85:1843-9.
5. Schroeder JR, Saah AJ, Hoover DR, Margolick JB, Ambinder RF, Martinez-Maza O, et al. Serum soluble CD23 level correlates with subsequent development of AIDS-related non-Hodgkin's lymphoma. Cancer Epidemiol Biomarkers Prev 1999;8:979-84.
6. Breen EC, van der MM, Cumberland W, Kishimoto T, Detels R, Martinez-Maza O. The development of AIDS-associated Burkitt's/small noncleaved cell lymphoma is preceded by elevated serum levels of interleukin 6. Clin Immunol 1999;92:293-9.
7. Breen EC, Hussain SK, Magpantay L, Jacobson LP, Detels R, Rabkin CS, et al. B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-associated non-Hodgkin B-cell lymphoma. Cancer Epidemiol Biomarkers Prev 2011;20:1303-14.
8. Widney D, Gundapp G, Said JW, van der MM, Bonavida B, Demidem A, et al. Aberrant expression of CD27 and soluble CD27 (sCD27) in HIV infection and in AIDS-associated lymphoma. Clin Immunol 1999;93:114-23.
9. Breen EC, Fatahi S, Epeldegui M, Boscardin WJ, Detels R, Martinez- Maza O. Elevated serum soluble CD30 precedes the development of AIDS-associated non-Hodgkin's B cell lymphoma. Tumour Biol 2006;27:187-94.
10. Breen EC, Epeldegui M, Boscardin WJ, Widney DP, Detels R, Martinez- Maza O. Elevated levels of soluble CD44 precede the development of AIDS-associated non-Hodgkin's B-cell lymphoma. AIDS 2005;19:1711-2.
11. Widney DP, Breen EC, Boscardin WJ, Kitchen SG, Alcantar JM, Smith JB, et al. Serum levels of the homeostatic B cell chemokine, CXCL13, are elevated during HIV infection. J Interferon Cytokine Res 2005;25:702-6.
12. Widney DP, Gui D, Popoviciu LM, Said JW, Breen EC, Huang X, et al. Expression and Function of the Chemokine, CXCL13, and Its Receptor, CXCR5, in Aids-Associated Non-Hodgkin's Lymphoma. AIDS Res Treat 2010;2010:164586.
13. Purdue MP, Lan Q, Martinez-Maza O, Oken MM, Hocking W, Huang WY, et al. A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma. Blood 2009;114:2730-2.
14. Vermeulen R, Hosnijeh FS, Portengen L, Krogh V, Palli D, Panico S, et al. Circulating soluble CD30 and future risk of lymphoma; evidence from two prospective studies in the general population. Cancer Epidemiol Biomarkers Prev 2011;20:1925-7.
15. Purdue MP, Lan Q, Bagni R, Hocking WG, Baris D, Reding DJ, et al. Prediagnostic serum levels of cytokines and other immune markers and risk of non-hodgkin lymphoma. Cancer Res 2011;71:4898-907.
16. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials 1998;19:61-109.
17. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, et al. eds. International classification of diseases for oncology, 3rd Edition. Geneva: World Health Organization; 2000.
18. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006;107:265-76.
19. Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood 2007;110:695-708.
20. Breslow NE, Day NE. Statistical methods in cancer research. Vol 1. The analysis of case-control studies. International Agency for Research on Cancer: Lyon, France; 1980.
21. Breen EC, Magpantay L, Hu Z, Jacobson L, Detels R, Rabkin C, et al. Serum levels of molecules that are markers of B cell activation are elevated prior to the development of acquired immunodeficiency syndrome-associated non-Hodgkin's B cell lymphoma. American Association of Cancer Research, Annual Meeting 2006 #165. 2006.
22. Gordon J. CD23 and B cell activation. Clin Exp Allergy 1992;22:199-204.
23. Lens SM, Drillenburg P, den Drijver BF, van Schijndel G, Pals ST, van Lier RA, et al. Aberrant expression and reverse signalling of CD70 on malignant B cells. Br J Haematol 1999;106:491-503.
24. Nawrocki JF, Kirsten ES, Fisher RI. Biochemical and structural properties of a Hodgkin's disease-related membrane protein. J Immunol 1988;141:672-80.
25. Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol 2003;3:609-20.
26. Younes A, Aggarwall BB. Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders. Cancer 2003;98:458-67.
27. Lens SM, Tesselaar K, van Oers MH, van Lier RA. Control of lymphocyte function through CD27-CD70 interactions. Semin Immunol 1998;10:491-9.
28. Muller G, Hopken UE, Stein H, Lipp M. Systemic immunoregulatory and pathogenic functions of homeostatic chemokine receptors. J Leukoc Biol 2002;72:1-8.
29. van Oers MH, Pals ST, Evers LM, van der Schoot CE, Koopman G, Bonfrer JM, et al. Expression and release of CD27 in human B-cell malignancies. Blood 1993;82:3430-6.
30. Landgren O, Albitar M, Ma W, Abbasi F, Hayes RB, Ghia P, et al. B-cell clones as early markers for chronic lymphocytic leukemia. N Engl J Med 2009;360:659-67.
31. Rawstron AC, Bennett FL, O'Connor SJ, Kwok M, Fenton JA, Plummer M, et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med 2008;359:575-83.
32. Meuleman N, Stamatopoulos B, Dejeneffe M, El HH, Lagneaux L, Bron D. Doubling time of soluble CD23: a powerful prognostic factor for newly diagnosed and untreated stage A chronic lymphocytic leukemia patients. Leukemia 2008;22:1882-90.
33. Rawstron AC, Shingles J, de TR, Bennett F, Jack AS, Hillmen P. Chronic lymphocytic leukaemia (CLL) and CLL-type monoclonal Bcell lymphocytosis (MBL) show differential expression of molecules involved in lymphoid tissue homing. Cytometry B Clin Cytom 2010;78 Suppl 1:S42-46.